PTC Therapeutics Inc
NASDAQ:PTCT

Watchlist Manager
PTC Therapeutics Inc Logo
PTC Therapeutics Inc
NASDAQ:PTCT
Watchlist
Price: 43.23 USD 0.79% Market Closed
Market Cap: 3.3B USD
Have any thoughts about
PTC Therapeutics Inc?
Write Note

PTC Therapeutics Inc
Goodwill

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PTC Therapeutics Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
PTC Therapeutics Inc
NASDAQ:PTCT
Goodwill
$82.3m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Goodwill
$35.3B
CAGR 3-Years
3%
CAGR 5-Years
18%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Goodwill
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
15%
CAGR 10-Years
22%
Amgen Inc
NASDAQ:AMGN
Goodwill
$18.7B
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Goodwill
$1.1B
CAGR 3-Years
3%
CAGR 5-Years
19%
CAGR 10-Years
43%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PTC Therapeutics Inc
Glance View

Market Cap
3.3B USD
Industry
Biotechnology

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. The company is headquartered in South Plainfield, New Jersey and currently employs 1,252 full-time employees. The company went IPO on 2013-06-20. The Company’s portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company’s gene therapy platform focuses on the development of therapies for rare and debilitating diseases of the nervous system (CNS). The Company’s splicing platform focuses on the development of therapies for diseases, such as SMA, that involve regulation of messenger RNA (mRNA) splicing in the cell.

PTCT Intrinsic Value
45.53 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is PTC Therapeutics Inc's Goodwill?
Goodwill
82.3m USD

Based on the financial report for Jun 30, 2024, PTC Therapeutics Inc's Goodwill amounts to 82.3m USD.

What is PTC Therapeutics Inc's Goodwill growth rate?
Goodwill CAGR 5Y
0%

Over the last year, the Goodwill growth was 0%.

Back to Top